Immunomedics, Inc. announced the appointment of Barbara G. Duncan to the Company’s Board of Directors and as the Chairperson of the Audit Committee. Ms. Duncan has over 30 years of financial leadership experience, of which 17 are in the life sciences industry. Ms. Duncan previously served as Chief Financial Officer and Treasurer at Intercept Pharmaceuticals, Inc. Prior to her leadership role with Intercept, Ms. Duncan was Chief Financial Officer and then Chief Executive Officer at DOV Pharmaceutical Inc., which was sold to Euthymics Bioscience, Inc. in 2010. Ms. Duncan currently serves on the Board of Directors of Aevi Genomic Medicine, Inc., Adaptimmune Therapeutics, plc, Jounce Therapeutics, Inc., ObsEva SA, and OVID Therapeutics Inc.